Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors

已报道的组蛋白乙酰转移酶抑制剂的检测干扰和脱靶责任

阅读:11
作者:Jayme L Dahlin, Kathryn M Nelson, Jessica M Strasser, Dalia Barsyte-Lovejoy, Magdalena M Szewczyk, Shawna Organ, Matthew Cuellar, Gurpreet Singh, Jonathan H Shrimp, Nghi Nguyen, Jordan L Meier, Cheryl H Arrowsmith, Peter J Brown, Jonathan B Baell, Michael A Walters

Abstract

Many compounds with potentially reactive chemical motifs and poor physicochemical properties are published as selective modulators of biomolecules without sufficient validation and then propagated in the scientific literature as useful chemical probes. Several histone acetyltransferase (HAT) inhibitors with these liabilities are now routinely used to probe epigenetic pathways. We profile the most commonly used HAT inhibitors and confirm that the majority of them are nonselective interference compounds. Most (15 out of 23, 65%) of the inhibitors are flagged by ALARM NMR, an industry-developed counter-screen for promiscuous compounds. Biochemical counter-screens confirm that most of these compounds are either thiol-reactive or aggregators. Selectivity panels show many of these compounds modulate unrelated targets in vitro, while several also demonstrate nonspecific effects in cell assays. These data demonstrate the usefulness of performing counter-screens for bioassay promiscuity and assay interference, and raise caution about the utility of many widely used, but insufficiently validated, compounds employed in chemical biology.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。